SCHEMBL2172572

SCHEMBL2172572

COCOCCc1ccc(C(O)c2cc(Br)c(OCc3ccccc3)cc2Cl)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.34
ALDH1A1 P00352 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 1/20 0.34
RAB9A P51151 1/20 0.34
HTR1A P08908 1/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
BCHE P06276 2/20 0.33
CCR5 P51681 1/20 0.33
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
THRA P10827 1/20 0.33
THRB P10828 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2174329 0.89 FFAR4 (0.36) SMN1; SMN2MEN1KMT2ARAB9ABCHE
SCHEMBL14384679 0.86 GLA (0.36) SMN1; SMN2KDM4ETHRATHRB
SCHEMBL12407955 0.81
SCHEMBL2173652 0.81 ABCB1 (0.38) SMN1; SMN2ALDH1A1KDM4ENPSR1HTT
SCHEMBL14385177 0.77 HPGD (0.36) CYP3A4CYP2D6
SCHEMBL2174782 0.77 HPGD (0.36) CYP3A4CYP2D6
SCHEMBL6809786 0.77 RAB9A (0.46) SMN1; SMN2KDM4EMEN1KMT2ARAB9A
SCHEMBL20139486 0.76 HTR2A (0.40) SMN1; SMN2MEN1KMT2ARAB9ACCR5
SCHEMBL4000423 0.74 DRD2 (0.41) SMN1; SMN2ABCB1
SCHEMBL2172626 0.74 ABCB1 (0.39) SMN1; SMN2MEN1MAPK1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2076503-B1 C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES TAISHO PHARMACEUTICAL CO LTD (JP) 2013-07-17 EP disclosed
US-7973012-B2 C-phenyl glycitol compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-07-05 US disclosed
US-20100022460-A1 C-PHENYL GLYCITOL COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-01-28 US disclosed
EP-2076503-A2 C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES TAISHO PHARMACEUTICAL CO., LTD (JP) 2009-07-08 EP disclosed
WO-2007136116-A2 C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022460-A1 C-PHENYL GLYCITOL COMPOUND SLC5A1, SLC5A2, SLC2A1 SMN1; SMN2 4544/4885ALDH1A1 704/4885KDM4E 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.